DAS181 is a novel inhaled
drug candidate blocking influenza virus (IFV) and
parainfluenza virus (PIV)
infections through removal of
sialic acid receptors from epithelial surface of the respiratory tract. To support clinical development, a 28-day Good Laboratory Practices inhalation toxicology study was conducted in Sprague-Dawley rats. In this study, achieved average daily doses based on exposure concentrations were 0.47, 0.90, 1.55, and 3.00 mg/kg/day of
DAS181 in a dry
powder formulation.
DAS181 was well tolerated at all dose levels, and there were no significant toxicological findings.
DAS181 administration did not affect animal
body weight, food consumption, clinical signs, ophthalmology, respiratory parameters, or organ weight. Gross pathology evaluations were unremarkable. Histological examination of the lungs was devoid of pulmonary tissue damage, and findings were limited to mild and transient changes indicative of exposure and clearance of a foreign
protein.
DAS181 did not show any cytotoxic effects on human and animal primary cells, including hepatocytes, skeletal muscle cells, osteoblasts, or respiratory epithelial cells.
DAS181 did not cause direct or indirect
hemolysis. A laboratory abnormality observed in the 28-day toxicology study was mild and transient
anemia in male rats at the 3.00 mg/kg dose, which is an expected outcome of enhanced clearance of desialylated red blood cells resulting from systemic exposure with
DAS181. Another laboratory observation was a transient dose-dependent elevation in
alkaline phosphatase (ALP), which can be attributed to reduced ALP clearance resulting from increased
protein desialylation due to
DAS181 systemic exposure. These laboratory parameters returned to normal at the end of the recovery period.